CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Operating revenue:
Personalized oncology solutions	$ 1,972,000	$ 1,663,000
Translational oncology solutions	9,210,000	7,200,000
Total operating revenue	11,182,000	8,863,000
Costs and operating expenses:
Cost of personalized oncology solutions	2,102,000	2,733,000
Cost of translational oncology solutions	6,584,000	4,900,000
Research and development	4,194,000	4,845,000
Sales and marketing	3,445,000	4,283,000
General and administrative	5,173,000	5,340,000
Total costs and operating expenses	21,498,000	22,101,000
Loss from operations	(10,316,000)	(13,238,000)
Other income/(expense):
Change in fair value of warrant liability	0	981,000
Warrant modification charge	0	(586,000)
Other expense	(38,000)	(170,000)
Total other income/(expense)	(38,000)	225,000
Net loss before income tax expense	(10,354,000)	(13,013,000)
Provision for income tax	92,000	127,000
Net loss	$ (10,445,537)	$ (13,139,820)
Net loss per common share outstanding basic and diluted (in dollars per share)	$ (1.20)	$ (2.20)
Weighted average common shares outstanding basic and diluted (in shares)	8,695,199	5,985,346